NASDAQ:TECX Tectonic Therapeutic Q4 2024 Earnings Results & Report $21.06 -0.25 (-1.15%) As of 01:48 PM Eastern This is a fair market value price provided by Massive. Learn more. Tectonic Therapeutic beat analyst earnings expectations in its Q4 2024 results, released March 20, 2025. The company reported EPS of -$0.84 versus the -$1.39 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2024Report DateMarch 20, 2025TimeBefore Market OpensConference Call4:00 PM ET Tectonic Therapeutic EPS ResultsActual EPS-$0.84Consensus EPS -$1.39Beat/MissBeat by +$0.55One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersTectonic Therapeutic Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsTectonic Therapeutic's Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Tectonic Therapeutic Q4 2024 Earnings FAQ Did Tectonic Therapeutic beat earnings estimates for Q4 2024? Tectonic Therapeutic (NASDAQ:TECX) reported earnings of -$0.84 per share for Q4 2024, beating the consensus estimate of -$1.39. The report was announced on Thursday, March 20, 2025. When is Tectonic Therapeutic's next earnings date? Tectonic Therapeutic's next earnings date is estimated for Thursday, November 5, 2026. MarketBeat tracks confirmed and estimated earnings dates for Tectonic Therapeutic on the company's earnings history page. Tectonic Therapeutic Earnings HeadlinesTectonic Therapeutic (NASDAQ:TECX) Stock Rating Raised to Sell at Wall Street ZenOctober 10, 2026 | americanbankingnews.comTectonic Therapeutic (NASDAQ:TECX) Insider Peter Mcnamara Sells 536 Shares of StockOctober 3, 2026 | americanbankingnews.comFederal Reserve Reveals Disturbing New Plan To Control Your MoneyDocket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on page 84 is a plan that could expand oversight of checking accounts, purchases, and money transfers across the country. Martin D. Weiss, PhD, founder of Weiss Ratings, breaks down what this document means and why it could roll out as soon as this summer.October 14 at 1:00 AM | Weiss Ratings (Ad)Analysts Offer Insights on Healthcare Companies: Tectonic Therapeutic (TECX) and Solid Biosciences (SLDB)October 1, 2026 | theglobeandmail.comTectonic Therapeutic Says TX2100 Phase 1a Trial Met Primary ObjectivesSeptember 29, 2026 | finance.yahoo.comTectonic Therapeutic Announces Favorable Phase 1 Safety, Tolerability and PK Results for TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT)September 29, 2026 | globenewswire.comSee More Tectonic Therapeutic Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Tectonic Therapeutic? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tectonic Therapeutic and other key companies, straight to your email. Email Address About Tectonic TherapeuticTectonic Therapeutic (NASDAQ:TECX) (NASDAQ: TECX) is a clinical-stage biotechnology company developing biologic medicines that target G protein-coupled receptors (GPCRs). These receptors play important roles in numerous biological processes and are established targets for a range of therapeutic treatments, but many remain difficult to address with conventional drug-discovery approaches. The company uses its proprietary GEODe platform to identify and develop antibodies and other biologic molecules designed to modulate GPCR activity. Its research and development efforts are focused on creating therapies for serious diseases in areas where current treatment options may be limited. Tectonic’s lead program, TX45, is an engineered relaxin-based therapeutic intended to activate the RXFP1 receptor. The program has been investigated for potential treatment of pulmonary arterial hypertension and other cardiovascular conditions. Tectonic Therapeutic is based in the United States and focuses primarily on advancing its internal discovery and clinical development pipeline.View Tectonic Therapeutic ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Citi Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenPBF Energy's Stunning Rally Faces a Critical TestA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Albertsons Is Betting on a Turnaround—But Will It Pay Off?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American BusinessTax Credit Turmoil: Why Enphase and SolarEdge Face a Tough Road Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
